ASX-listed MGC Pharmaceuticals has achieved major progress in its potentially breakthrough anti-cancer research which aims to develop a treatment for one of the most serious forms of brain cancer after receiving more successful results from the pre-clinical program based in Slovenia.
The Perth-based medical cannabis company said on Tuesday the successful results from an ongoing in-vitro program would enable it to push ahead to a clinical trial as part of the research focused on the use of Cannabidiol (CBD) and Cannabigerol (CBG) to treat glioblastoma — one of the most aggressive and therapeutically resistant brain tumours known to man.
According to MGC, the world-first results, derived from an additional 18 patient tumour samples taken this year and demonstrated the efficacy of its proprietary CBD:CBG formulation on glioblastoma cancer by showing the substances can help kill the potentially deadly cancers cells.
MGC co-founder and Managing Director Roby Zomer said the latest results meant it could streamline the drug development and registration process moving ahead, paving the way for a clinical trial to occur.
The results we have seen in our preclinical work on glioblastoma have continued to be very encouraging.
We are constantly learning more about the therapeutic benefits of medicinal cannabinoids in the treatment of a number of medical conditions and are pleased to report that the Company will now begin preparations for the next stage of clinical trial work on glioblastoma.
In what the medical marijuana player sees as a major step forward for its anti-cancer research, the results showed, for the first time, that CBG both impairs the “major hallmarks” of glioblastoma progression and could destroy therapy-resistant glioblastoma stem cells that are usually extremely resistant to various treatments of the highly lethal cancer.
The results related to CBD were similarly pleasing, with the latest tranche of research demonstrating that the cannabis-derived substance could “inhibit” the viability of glioblastoma tumours, the company said.
Today’s news from the ASX junior comes after the Europe-based program returned successful results in April. The research is being undertaken in collaboration with the highly respected National Institute of Biology and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia.
Looking ahead, the success in the latest tumour tests means focus now turns to animal trials in zebrafish and rodents and then human clinical trials, with submissions on those scheduled for next year, MGC said.
The company’s anti-cancer research is one of multiple potential business revenue streams in the works at the medical cannabis firm. Others include the production and sales of its ArtemiC natural supplement, its medicinal cannabis-based epilepsy formula CannEpil and trials of ArtemiC in spray form as a potential anti-inflammatory treatment for Coronavirus.
In September, the company struck a major funding deal with US-based investment group, Mercer Street Global Opportunity Fund, that allows MGC Pharmaceuticals to draw on a financing facility of up to $15 million to fast track its clinical trial and research programs.
Is your ASX listed company doing something interesting? Contact: [email protected]
Get the latest news from thewest.com.au in your inbox.
Sign up for our emails